Browsing Tag
Belite Bio
3 posts
Tarsus Pharmaceuticals (NASDAQ: TARS) to add Alkeus in $800m eye pipeline deal
Tarsus lines up an $800m Alkeus deal and a $125m PIPE to enter Stargardt disease, but a 2029 readout and Belite Bio's lead still gate the retina thesis.
Why investors are watching Belite Bio after the tinlarebant NDA submission
Find out how Belite Bio’s tinlarebant FDA filing could reshape rare eye disease treatment and investor sentiment today.
Belite Bio wins UK MHRA nod to file conditional marketing application for tinlarebant in Stargardt disease
Find out how Belite Bio gained UK MHRA backing to file a conditional marketing application for tinlarebant, advancing the first potential therapy for Stargardt disease.